SEC Filings

Form 10-Q
IOVANCE BIOTHERAPEUTICS, INC. filed this Form 10-Q on 08/07/2018
Document Outline
Entire Document (3352.3 KB)
Subdocument 1 - 10-Q - FORM 10-Q
Page 1 - U. S. SECURITIES AND EXCHANGE COMMISSION
Page 2 - IOVANCE BIOTHERAPEUTICS, INC.
Page 3 - PART I. FINANCIAL INFORMATION
Page 4 - IOVANCE BIOTHERAPEUTICS, INC.
Page 5 - IOVANCE BIOTHERAPEUTICS, INC.
Page 6 - IOVANCE BIOTHERAPEUTICS, INC.
Page 7 - IOVANCE BIOTHERAPEUTICS, INC.
Page 8 - NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Page 9 - Use of Estimates
Page 10 - Preferred Stock
Page 11 - Recent Accounting Standards Not Yet Adopted
Page 12 - NOTE 4. BALANCE SHEET COMPONENTS
Page 13 - Warrants
Page 14 - Restricted Stock Units
Page 15 - NOTE 7. LICENSES AND AGREEMENTS
Page 16 - H. Lee Moffitt Cancer Center
Page 17 - PolyBioCept and Karolinska University Hospital
Page 18 - WuXi Apptech, Inc. ( WuXi )
Page 19 - N/A
Page 20 - NOTE 9. COMMITMENTS AND CONTINGENCIES
Page 21 - Forward-Looking Statements
Page 22 - Results of Operations
Page 23 - N/A
Page 24 - Liquidity and Capital Resources
Page 25 - Off-Balance Sheet Arrangements
Page 26 - PART II. OTHER INFORMATION
Page 27 - N/A
Page 28 - Risks Related to Our Business
Page 29 - We have limited experience as a company conducting clinical trials and face risks due to the need to
Page 30 - N/A
Page 31 - We may encounter substantial delays in our clinical trials or may not be able to conduct our trials
Page 32 - It may take longer and cost more to complete our clinical trials than we project, or we may not be a
Page 33 - Clinical trials are expensive, time-consuming and difficult to design and implement, and our clinica
Page 34 - If we encounter difficulties enrolling patients in our clinical trials, our clinical development act
Page 35 - Our product candidates may cause undesirable side effects or have other properties that could halt t
Page 36 - The manufacture of our product candidates is complex, and we may encounter difficulties in productio
Page 37 - Cell-based therapies rely on the availability of reagents, specialized equipment, and other specialt
Page 38 - The deviations in our proposed new products from existing products may require us to perform additio
Page 39 - Our historical research and development efforts have been to a large extent dependent upon the CRADA
Page 40 - Subject to various spending levels approved by the Board of Directors, our management will have broa
Page 41 - The use of our net operating loss carryforwards and research tax credits may be limited. *
Page 42 - We may not be able to license new TIL technology from the NIH and others.
Page 43 - No assurance can be given that the Gen 2 manufacturing process we have selected will be, FDA-complia
Page 44 - We face significant competition from other biotechnology and pharmaceutical companies and from non-p
Page 45 - We are dependent on third parties to support our research, development and manufacturing activities
Page 46 - Development of a product candidate intended for use in combination with an already approved product
Page 47 - A Fast Track product designation or other designation to facilitate product candidate development ma
Page 48 - If our product candidates do not achieve broad market acceptance, the revenues that we generate from
Page 49 - Our product candidates may face competition sooner than anticipated.
Page 50 - Our internal computer systems, or those used by our contract research organizations or other contrac
Page 51 - If we engage in future acquisitions or strategic partnerships, this may increase our capital require
Page 52 - The SEC has issued an administrative order against us that may make it more difficult for us to rais
Page 53 - Risks Related to Government Regulation
Page 54 - We are, and if we receive regulatory approval of our product candidates, will continue to be subject
Page 55 - If we fail to comply with federal and state healthcare and promotional laws, including fraud and abu
Page 56 - Coverage and reimbursement may be limited or unavailable in certain market segments for our product
Page 57 - N/A
Page 58 - We are subject to new legislation, regulatory proposals, and healthcare payor initiatives that may i
Page 59 - Our employees, independent contractors, consultants, commercial partners and vendors may engage in m
Page 60 - We may incur substantial costs as a result of litigation or other proceedings relating to patent and
Page 61 - We cannot prevent other companies from licensing most of the same intellectual properties that we ha
Page 62 - We may be subject to claims that our employees, consultants or independent contractors have wrongful
Page 63 - You may experience future dilution as a result of future equity offerings or other equity issuances.
Page 64 - We do not anticipate paying cash dividends for the foreseeable future, and therefore investors shoul
Page 65 - N/A
Page 66 - EXHIBIT
Page 67 - SIGNATURES
Subdocument 2 - EX-10.2 - EXHIBIT 10.2
Page 1 - Exhibit 10.2
Page 2 - 3. Termination of Employment or Services.
Page 3 - 5. Method of Exercise and Form of Payment.
Page 4 - 7. Compliance with Legal Requirements.
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Subdocument 3 - EX-10.3 - EXHIBIT 10.3
Page 1 - Exhibit 10.3
Page 2 - 3. Termination of Employment or Services.
Page 3 - 5. Method of Exercise and Form of Payment.
Page 4 - 7. Compliance with Legal Requirements.
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Subdocument 4 - EX-31.1 - EXHIBIT 31.1
Page 1 - N/A
Subdocument 5 - EX-31.2 - EXHIBIT 31.2
Page 1 - N/A
Subdocument 6 - EX-32.1 - EXHIBIT 32.1
Page 1 - N/A
Subdocument 7 - EX-32.2 - EXHIBIT 32.2
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE (What's this?)
XBRL Viewer